Insider Transactions in Q1 2023 at Reata Pharmaceuticals Inc (RETA)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 13
2023
|
Dawn Carter Bir Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
9,317
-22.44%
|
$801,262
$86.77 P/Share
|
|
Mar 10
2023
|
Shamim Ruff Director |
SELL
Open market or private sale
|
Direct |
5,740
-52.36%
|
$476,420
$83.73 P/Share
|
|
Mar 10
2023
|
Shamim Ruff Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,740
+15.91%
|
$183,680
$32.28 P/Share
|
|
Mar 07
2023
|
Andrea Loewen SVP, Global Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
19,036
-16.93%
|
$1,579,988
$83.9 P/Share
|
|
Mar 07
2023
|
Andrea Loewen SVP, Global Regulatory Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+20.61%
|
$405,000
$27.32 P/Share
|
|
Mar 07
2023
|
Dawn Carter Bir Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
42,042
-18.61%
|
$3,573,570
$85.88 P/Share
|
|
Mar 07
2023
|
Dawn Carter Bir Chief Commercial Officer |
BUY
Conversion of derivative security
|
Direct |
41,630
+33.25%
|
-
|
|
Mar 07
2023
|
Bhaskar Anand SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
165
-0.61%
|
$13,860
$84.58 P/Share
|
|
Mar 07
2023
|
Manmeet Singh Soni COO, CFO and President |
SELL
Open market or private sale
|
Direct |
622
-0.7%
|
$52,248
$84.69 P/Share
|
|
Mar 07
2023
|
Colin John Meyer Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
621
-0.73%
|
$52,164
$84.57 P/Share
|
|
Mar 07
2023
|
Samina Khan SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,961
-8.98%
|
$328,763
$83.46 P/Share
|
|
Mar 07
2023
|
Michael D Wortley Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
414
-0.85%
|
$34,776
$84.46 P/Share
|
|
Mar 06
2023
|
Dawn Carter Bir Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
54,954
-33.77%
|
$4,890,906
$89.78 P/Share
|
|
Mar 06
2023
|
Dawn Carter Bir Chief Commercial Officer |
BUY
Conversion of derivative security
|
Direct |
48,370
+33.3%
|
-
|
|
Mar 03
2023
|
R Kent Mc Gaughy Jr |
SELL
Bona fide gift
|
Indirect |
33,217
-100.0%
|
-
|
|
Mar 03
2023
|
Colin John Meyer Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
5,286
-5.84%
|
$459,882
$87.35 P/Share
|
|
Mar 03
2023
|
Michael D Wortley Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,169
-4.28%
|
$188,703
$87.57 P/Share
|
|
Mar 03
2023
|
Andrea Loewen SVP, Global Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
1,601
-3.61%
|
$139,287
$87.73 P/Share
|
|
Mar 03
2023
|
Manmeet Singh Soni COO, CFO and President |
SELL
Open market or private sale
|
Direct |
3,587
-3.88%
|
$312,069
$87.97 P/Share
|
|
Mar 03
2023
|
Samina Khan SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,813
-6.0%
|
$244,731
$87.36 P/Share
|
|
Mar 03
2023
|
Bhaskar Anand SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
820
-2.96%
|
$71,340
$87.47 P/Share
|
|
Mar 03
2023
|
Dawn Carter Bir Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,166
-4.27%
|
$190,608
$88.25 P/Share
|
|
Mar 02
2023
|
Colin John Meyer Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
88,636
-12.49%
|
$7,711,332
$87.67 P/Share
|
|
Mar 02
2023
|
Colin John Meyer Chief Innovation Officer |
BUY
Conversion of derivative security
|
Direct |
88,636
+33.1%
|
-
|
|
Mar 02
2023
|
Andrea Loewen SVP, Global Regulatory Affairs |
SELL
Open market or private sale
|
Direct |
218
-0.49%
|
$19,620
$90.61 P/Share
|
|
Mar 02
2023
|
Samina Khan SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,000
-12.58%
|
$2,100,000
$84.7 P/Share
|
|
Mar 02
2023
|
Samina Khan SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+25.8%
|
$675,000
$27.32 P/Share
|
|
Mar 02
2023
|
James Warren Huff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
75,000
-9.57%
|
$6,450,000
$86.4 P/Share
|
|
Mar 01
2023
|
James Warren Huff Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
75,000
+40.29%
|
-
|
|
Mar 01
2023
|
Bhaskar Anand SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+9.76%
|
-
|
|
Feb 28
2023
|
Colin John Meyer Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+14.22%
|
-
|
|
Jan 03
2023
|
James Warren Huff Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,025
+50.0%
|
-
|
|
Jan 03
2023
|
Michael D Wortley Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,675
+23.62%
|
-
|
|
Jan 03
2023
|
Manmeet Singh Soni COO, CFO and President |
BUY
Grant, award, or other acquisition
|
Direct |
23,513
+20.27%
|
-
|
|
Jan 03
2023
|
Colin John Meyer Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,513
+23.74%
|
-
|
|
Jan 03
2023
|
Andrea Loewen SVP, Global Regulatory Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
11,756
+20.86%
|
-
|
|
Jan 03
2023
|
Samina Khan SVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,756
+20.04%
|
-
|
|
Jan 03
2023
|
Dawn Carter Bir Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,675
+23.62%
|
-
|
|
Jan 03
2023
|
Bhaskar Anand SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,250
+25.0%
|
-
|